RE:RE:SplitJust to be clear, there's never been a change of direction. Tripp knew that all along he even invited us to educate ourselves in a recent interview about how the regulations of cancer tests in the US. But he never thought it would be good to inform shareholders before Aristotle, neither his institutionnal investors afaik, that were fighting hard against the shorts to prepare a breakout for the launch that was almost a non event. I couldn't believe it.
davewho wrote: the sp did pretty well after the last RS as I recall. It was the botched release of Aristotle, the unknowns around the Care deal and the change of direction of how to market Aristotle that messed things up. Plus the downgrade didn't help.